

RECEIVED  
CENTRAL FAX CENTER

001

JUL 09 2007

PATENT  
Client Reference Number: WH-14

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on July 9, 2007

Date

Signature

Sam Zaghmout

Dr. O. M. (Sam) Zaghmout

Typed or printed name of person signing Certificate

Attachments: \_\_\_\_\_

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mukarram et al.

Application Serial Number: 10/564,364

Filing Date: 02-23-2006

Title: A Novel Process for the Manufacture of (+)-(S)-Clopidogrel Bisulfate Form- I

Examiner: Nizal S. Chandrakumar

Art Unit: 1625

Date: July 9, 2007

Mail Stop: Patent Application (Response to Examiner's amendment-suggested by the Examiner on the Phone on June 25, 2007)

Honorable Commissioner for Patents  
P.O. Box 1450 Alexandria, VA 22313-1450

Dear Mr. Chandrakumar:

To follow up on the phone conversation that I had with you yesterday (July 8, 2007), Applicants would accept the Examiner's Amendment to the extent that you have proposed over the phone on June 25, 2007.

As per your suggestion, Claims 21-23 would be amended as follow:

21. The Form-I of clopidogrel bisulfate ~~having of claim 20, wherein the clopidogrel~~ has a melting point of 198°C to 200 °C.
22. The Form-I of clopidogrel bisulfate of claim 21, wherein the clopidogrel ~~bisulfate~~ has a purity of more than 99% by HPLC.
23. The Form-I of clopidogrel bisulfate of claim 22, wherein the clopidogrel ~~bisulfate~~ has a purity of more than 99.96%.

A copy of the amended claims is in page 2.

Page 1 of 3, 10:55 AM, 7/9/2007, response to an Examiner's amendment. Applicant: Mukarrams et al.  
Application Serial Number: 10/564,364; Filing Date: 02-23-2006; Title: A Novel Process for the Manufacture of (+)-(S)-Clopidogrel Bisulfate Form- I; Examiner: Nizal S. Chandrakumar, Art Unit: 1625